Trimethoprim
|
|
|
Missing image | |
|
2,4-diamino-5- | |
| Empirical formula | C14H18N4O3 |
| Molecular weight | 290.3 |
| Bioavailability (Oral) | 90-100% |
| Metabolism | hepatic |
| Half life | 8-10 hours (adults, normal renal function); 20-50 hours (adults, severe renal impairment) |
| Excretion | renal |
| Pregnancy category | B3 (Australia) |
Trimethoprim is a bacteriostatic antibiotic mainly used in the prophylaxis and treatment of urinary tract infections (cystitis). It belongs to the class of chemotherapeutic agents known as dihydrofolate reductase inhibitors. Trimethoprim was formerly marketed by GlaxoWellcome under trade names including Proloprim®, Monotrim® and Triprim®; but these trade names have been licensed to various generic pharmaceutical manufacturers.
| Contents |
Mechanism of action
Trimethoprim acts by interfering with the action of bacterial dihydrofolate reductase, inhibiting synthesis of tetrahydrofolic acid. Folic acid is an essential precursor in the de novo synthesis of the DNA nucleosides thymidine and uridine. Bacteria are unable to take up folic acid from the environment (i.e. the infection host) thus are dependent on their own de novo synthesis - inhibition of the enzyme starves the bacteria of two bases necessary for DNA replication and transcription.
THFsynthesispathway.png
Co-trimoxazole
Trimethoprim is commonly used in combination with sulfamethoxazole, a sulfonamide antibiotic, which inhibits the an earlier step in the folate synthesis pathway (see diagram above). This combination, known as co-trimoxazole, results in a synergistic antibacterial effect by inhibiting successive steps in folate synthesis. Its use has been declining due to reports of sulfamethoxazole bone marrow toxicity.
Clinical indications
Trimethoprim, used as monotherapy, is indicated for the prophylaxis and treatment of urinary tract infections (cystitis). Co-trimoxazole, owing to its greater efficacy, is indicated for a wider range of infections. For example, it is used as prophylaxis in patients at risk for Pneumocystis carinii pneumonia (e.g. AIDS patients and those with some hematological malignancies), as therapy in Whipple's disease and certain other infections.
External links
- Nucleic acid inhibitors (http://www.med.sc.edu:96/Biopharm/PDFs/NucleicAcidInhibitors.pdf) (PDF file).